Fate Therapeutics, Inc. (FATE)
FATE Stock Price Chart
Explore Fate Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze FATE price movements and trends.
FATE Company Profile
Discover essential business fundamentals and corporate details for Fate Therapeutics, Inc. (FATE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 Oct 2013
Employees
181.00
Website
https://www.fatetherapeutics.comCEO
Bahram Valamehr
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE Financial Timeline
Browse a chronological timeline of Fate Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.31, while revenue estimate is $1.66M.
Earnings released on 12 Aug 2025
EPS came in at -$0.29 surpassing the estimated -$0.35 by +17.14%, while revenue for the quarter reached $1.91M , beating expectations by +65.98%.
Earnings released on 13 May 2025
EPS came in at -$0.32 surpassing the estimated -$0.39 by +17.95%, while revenue for the quarter reached $1.63M , beating expectations by +37.53%.
Earnings released on 5 Mar 2025
EPS came in at -$0.31 surpassing the estimated -$0.44 by +29.55%, while revenue for the quarter reached $1.86M , beating expectations by +18.57%.
Earnings released on 12 Nov 2024
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $3.07M , beating expectations by +132.88%.
Earnings released on 13 Aug 2024
EPS came in at -$0.33 surpassing the estimated -$0.47 by +29.79%, while revenue for the quarter reached $6.77M , beating expectations by +380.28%.
Earnings released on 9 May 2024
EPS came in at -$0.47 matching the estimated -$0.47, while revenue for the quarter reached $1.93M , beating expectations by +73.42%.
Earnings released on 26 Feb 2024
EPS came in at -$0.45 surpassing the estimated -$0.57 by +21.05%, while revenue for the quarter reached $1.68M , beating expectations by +5.41%.
Earnings released on 8 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$0.59 by +22.03%, while revenue for the quarter reached $1.94M , beating expectations by +18.54%.
Earnings released on 8 Aug 2023
EPS came in at -$0.54 surpassing the estimated -$0.58 by +6.90%, while revenue for the quarter reached $933.00K , missing expectations by -83.13%.
Earnings released on 3 May 2023
EPS came in at -$0.19 surpassing the estimated -$0.55 by +65.45%, while revenue for the quarter reached $58.98M , beating expectations by +66.14%.
Earnings released on 28 Feb 2023
EPS came in at -$0.58 surpassing the estimated -$0.86 by +32.56%, while revenue for the quarter reached $44.36M , beating expectations by +148.07%.
Earnings released on 3 Nov 2022
EPS came in at -$0.86 surpassing the estimated -$0.93 by +7.53%, while revenue for the quarter reached $14.98M , missing expectations by -1.96%.
Earnings released on 3 Aug 2022
EPS came in at -$0.79 surpassing the estimated -$0.86 by +8.14%, while revenue for the quarter reached $18.55M , beating expectations by +47.95%.
Earnings released on 4 May 2022
EPS came in at -$0.68 surpassing the estimated -$0.78 by +12.82%, while revenue for the quarter reached $18.41M , beating expectations by +104.34%.
Earnings released on 28 Feb 2022
EPS came in at -$0.72 falling short of the estimated -$0.68 by -5.88%, while revenue for the quarter reached $17.07M , beating expectations by +50.91%.
Earnings released on 4 Nov 2021
EPS came in at -$0.57 surpassing the estimated -$0.58 by +1.72%, while revenue for the quarter reached $14.23M , beating expectations by +80.29%.
Earnings released on 4 Aug 2021
EPS came in at -$0.58 falling short of the estimated -$0.52 by -11.54%, while revenue for the quarter reached $13.41M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at -$0.48 falling short of the estimated -$0.42 by -14.29%, while revenue for the quarter reached $11.14M , beating expectations by +13.16%.
Earnings released on 24 Feb 2021
EPS came in at -$0.38 matching the estimated -$0.38, while revenue for the quarter reached $15.90M , beating expectations by +39.04%.
Earnings released on 5 Nov 2020
EPS came in at -$0.36 falling short of the estimated -$0.29 by -24.14%, while revenue for the quarter reached $7.56M , beating expectations by +7.74%.
FATE Stock Performance
Access detailed FATE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.